Table 1.
Patient characteristics (n = 53)
| Patient characteristics | Mean (standard deviation) | n (%) |
|---|---|---|
| Age (y) | 68.2 (5.9) | |
| T stage | ||
| T1c | 18 (34) | |
| T2a | 15 (28) | |
| T2b | 10 (19) | |
| T2c | 5 (9) | |
| T3a | 2 (4) | |
| N+ | 2 (4) | |
| Gleason grade group | ||
| 1 (3 + 3) | 4 (8) | |
| 2 (3 + 4) | 26 (49) | |
| 3 (4 + 3) | 20 (38) | |
| 4 (4 + 4) | 2 (4) | |
| 5 (4 + 5) | 1 (2) | |
| Prostate-specific antigen level∗ (ng/mL) | 11.3 (6.1) | |
| <10 | 27 (51) | |
| 10-20 | 21 (40) | |
| >20 | 5 (9) | |
| Risk group | ||
| Intermediate | 43 (81) | |
| High | 10 (19) | |
| International Prostate Symptom Score∗ | 5.5 (4.3) | |
| ADT before HDR-BT | 29 (55) | |
| Length of ADT, if given (mo) | 4.0 (1.5) | |
| No. of biopsy cores taken ≥12 | 43 (81) | |
| Percent positive cores | 44.9 (19.2) | |
| Total tissue involved (%) | 18.6 (14.3) | |
| Prostate volume on ultrasound (cm3) | 32.9 (9.2) | |
| Contoured prostate volume (cm3) | 37.2 (10.1) | |
| Number of HDR-BT needles inserted | 15.1 (2.0; range, 11-18) |
Abbreviations: ADT = androgen deprivation therapy; HDR-BT = high-dose-rate brachytherapy
∗
International Prostate Symptom Score: 0-7 = mildly symptomatic; 8-19 = moderately symptomatic; 20-35 = severely symptomatic